Core Viewpoint - Micron Technology, Inc. is a leading player in the semiconductor industry, specializing in memory and storage solutions, particularly DRAM and NAND flash memory products, competing with major companies like Samsung and SK Hynix [1] Analyst Ratings and Price Targets - Brian Chin from Stifel Nicolaus has set a price target of $550 for Micron, indicating a potential increase of 33.38% from its current price of $412.37, which aligns with the consensus "Buy" rating from thirty-eight research firms [2][6] - Among the thirty-eight research firms, there are three "hold" ratings, twenty-nine "buy" ratings, and six "strong buy" ratings, with an average twelve-month price target of approximately $358, reflecting varied expectations among analysts [3] - Royal Bank of Canada has initiated coverage on Micron with an "outperform" rating and a price target of $425, while HSBC has raised its price target from $350 to $500, maintaining a "buy" rating [4] Current Stock Performance - Micron's current stock price is $412.37, reflecting a decrease of $3.19 or -0.77%, with a trading range today between $401.20 and $417.91; over the past year, the stock reached a high of $455.50 and a low of $61.54 [5] - The company's market capitalization is approximately $464.13 billion, with a trading volume of 22,246,699 shares on the NASDAQ exchange [5]

Core Insights - Roku, Inc. is a significant player in the streaming industry, competing with major platforms like Amazon Fire TV and Apple TV [1] - The stock is currently priced at $98.41, with a "Market Outperform" rating from Citigroup [1][6] Analyst Recommendations - Roku has received a "Moderate Buy" recommendation from twenty-eight analysts, including twenty-three buy recommendations, four hold recommendations, and one strong buy recommendation [2] - The average 12-month target price for Roku is approximately $124, indicating potential growth from its current price [2] - Arete Research has set a target price of $132, maintaining a "buy" rating since January 5th [3] - Guggenheim has increased their price target from $110 to $115 while maintaining a "buy" rating [3] - Raymond James Financial has a "market perform" rating for the stock [3] Stock Performance - Roku's stock has shown a 5.29% increase, with a price change of $4.94, currently trading at $98.41 [4][6] - The stock's daily trading range has been between $92.52 and $98.46 [4] - Over the past year, Roku's stock has fluctuated between a high of $116.66 and a low of $52.43 [4] Market Capitalization and Trading Volume - Roku's market capitalization is approximately $14.51 billion, reflecting its significant presence in the market [5][6] - The trading volume for Roku is 4,778,495 shares, indicating strong investor interest [5]

Core Insights - Driven Brands Holdings Inc. (NASDAQ:DRVN) is a significant entity in the automotive services sector, providing services such as car repair, maintenance, and car wash [1] - The company reported an earnings per share (EPS) of $0.29, surpassing the estimated EPS of $0.28 [5] - DRVN's actual revenue was approximately $457.3 million, which was slightly below the estimated revenue of $458.6 million [2][5] Financial Metrics - The company has a high debt-to-equity ratio of approximately 3.47, indicating a substantial reliance on debt financing [2][5] - DRVN's price-to-sales ratio is about 0.83, suggesting that investors are paying $0.83 for every dollar of sales, which is relatively low [3] - The enterprise value to sales ratio is around 2.00, and the enterprise value to operating cash flow ratio is approximately 16.12, indicating potential overvaluation relative to cash flow generation [3] - The current ratio of around 0.90 points to possible liquidity challenges in meeting short-term liabilities [4]

Company Overview - Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a key player in the medical technology sector, focusing on advanced silicone breast implants [1] Financial Performance - ESTA's Return on Invested Capital (ROIC) is -12.48%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 9.01%, indicating insufficient returns to cover capital costs [2] - The negative ROIC to WACC ratio for ESTA is -1.39, highlighting the company's challenges in generating adequate returns [2] Comparative Analysis - OrthoPediatrics Corp. (KIDS) has a ROIC of -6.27% and a WACC of 8.86%, resulting in a ROIC to WACC ratio of -0.71, which is better than ESTA's performance [3] - SI-BONE, Inc. (SIBN) shows a ROIC of -10.42% and a WACC of 7.50%, leading to a similar ROIC to WACC ratio of -1.39 as ESTA [3] - Crinetics Pharmaceuticals, Inc. (CRNX) faces a severe situation with a ROIC of -49.33% and a WACC of 4.44%, resulting in a ROIC to WACC ratio of -11.10 [4] - In contrast, LivaNova PLC (LIVN) has a positive ROIC of 10.90% and a WACC of 7.96%, achieving a favorable ROIC to WACC ratio of 1.37, indicating efficient capital utilization [4]

Core Insights - Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on therapies for neurological and immunoscience diseases, attracting investor and analyst attention due to its innovative treatment approaches [1] - The average price target for Biohaven increased to $23 last month, reflecting a positive outlook from analysts compared to the previous quarter, with BTIG setting a target of $24, indicating a potential rally of 82.2% [2][6] - Analysts' optimism is supported by an increase in the average price target from $18.67 three months ago to $23, suggesting favorable developments in clinical trials or market conditions [3] - A year ago, the average price target was $31.5, indicating challenges over the past year, but the recent upward trend suggests potential recovery and positive developments, with Biohaven receiving a Zacks Rank 2 (Buy) [4] - Recent news, including clinical trial progress and regulatory approvals, could significantly impact analysts' expectations and price targets, with positive developments likely leading to further increases [5]

Core Insights - Wave Life Sciences Ltd. is a clinical-stage genetic medicine company focused on developing stereopure oligonucleotides targeting RNA for therapeutic applications [1] - The consensus price target for WVE has increased from $29.79 last year to $32, indicating growing optimism among analysts [2] - The company is developing treatments for conditions such as amyotrophic lateral sclerosis, Huntington's disease, and Duchenne muscular dystrophy, with collaborations with Pfizer and Takeda enhancing its capabilities [3] - Despite reporting a quarterly loss of $0.30 per share, the company exceeded revenue estimates, providing some reassurance to investors [4] - Analyst Tiago Fauth from Wells Fargo has set a more cautious price target of $11 for WVE, reflecting a conservative outlook on the stock's future performance [5] Price Target Trends - The average consensus price target for WVE has shown a positive trend, increasing from $29.79 to $32 over the past year [2][6] - This upward trend suggests analysts are optimistic about the company's future prospects, likely due to advancements in clinical programs and collaborations [2][6] Company Developments - Wave Life Sciences is actively pursuing treatments for serious conditions and has established partnerships with major pharmaceutical companies, which may enhance its research capabilities and market reach [3][6] - The company's collaborations with Pfizer and Takeda are expected to contribute positively to its growth and investor sentiment [3] Financial Performance - In its Q4 2025 earnings call, Wave Life Sciences reported a loss of $0.30 per share, which was slightly below the Zacks Consensus Estimate of a $0.28 loss [4] - The reported loss marks a decline from the previous year's earnings of $0.17 per share, but the company managed to exceed revenue estimates, which may reassure investors [4][6]

In fact, our portfolio’s total return outperformance speaks for itself, as detailed here . If you are looking for a disciplined, income-focused strategy built around high-conviction ideas trading at compelling discounts, I encourage you to take a closer look at what we are building at High Yield Investor .Business development companies, or BDCs ( BIZD ), are a bit of a difficult asset class to fully understand for income investors. On the one hand, they look very, very attractive due to their juicy yields t ...

Regulated information Paris, March 2, 2026 DISCLOSURE FISCAL 2026/17 OF TRANSACTIONS ON TREASURY SHARES Period of: February 23 to February 27, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market. Issuer CodeTransaction dateISIN CodeDaily total volume (in number of shares)Daily weighted average price of shares acquiredPlatform213800RQNIQT48SEEO8523-Feb-26NL0015001W4942,00011.5877<td style="width:115.87px;;text-align: center ; vertica ...

Ernest HoffmanErnest Hoffman is a Crypto and Market Reporter for Kitco News. He has over 15 years of experience as a writer, editor, broadcaster and producer for media, educational and cultural organizations. Ernest began working in market news in 2007, establishing the broadcast division of CEP News in Montreal, Canada, where he developed the fastest web-based audio news service in the world and produced economic news videos in partnership with MSN and the TMX. He has a Bachelor's degree Specialization in ...

Core Insights - MKDWELL Tech Inc. has entered into a letter of intent with Sensor Electronics Co., Ltd. for the joint development of an agricultural machinery automation control system and related electronic integration solutions [1][2] - The collaboration will focus on developing Beidou terminal products and central integrated controllers for agricultural machinery, emphasizing precision operation and remote monitoring capabilities [1][2] - The partnership aims to address global challenges such as declining birth rates and a shrinking agricultural workforce across various regions [2] Company Overview - MKDWELL Tech Inc. is a manufacturer and supplier of automotive electronics, focusing on intelligent control systems and LiDAR sensors [3] - The company operates through a design center in Hsinchu Science Park, Taiwan, and a manufacturing plant in Jiaxing, China [3] - The company plans to accelerate the deployment of its intelligent agricultural solutions starting in mid-2026 [2]